We examined the presence of WT1-specific mRNA in bone marmyeloid leukemia (AML) to the French-American-British (FAB) Acute Leukemia Coop-
erative Group classification criteria after examination of bone marrow aspirates stained by a modification of Wright technique. In addition, immune phenotyping was performed in each case and karyotyping was attempted in all cases. Patient Introduction characteristics are shown in Table 1 . One hundred and sixteen out of 125 patients received one of the following induction A candidate Wilms' tumor gene (WT1 gene), located on protocols: DA (daunorubicin 45 mg/m 2 /day days 1-3, cytosine chromosome 11p13 has recently been identified. [1] [2] [3] WT1 is arabinoside 200 mg/m 2 /day as continuous infusion days 1-7, expressed in a time-and tissue-specific manner and the WT1 n = 36); DAV (daunorubicin 45 mg/m 2 /day days 1-3, cytosine transcript is mainly expressed in the developing kidney, testis, arabinoside 2 × 100 mg/m 2 /day days 1-7, etoposide ovary, spleen and cells of hematopoietic origin. 4, 5 The WT1 100 mg/m 2 /day days 1-5, n = 68). Twenty-eight of these gene consists of 10 exons, encoding a zinc finger transcription patients took part in a randomized filgrastim trial. One patient factor with a complex pattern of alternative splicing, with difreceived idarubicin instead of daunorubicin, one patient was ferent binding specificities and probably different targets. 6 treated with cytosine arabinoside only, 10 patients with M3 Recent data indicate that the WT1 gene product is involved received ATRA combined with or followed by chemotherapy. in transcriptional regulation. It recognizes the early growth Five patients died before the start of chemotherapy and four response-1 (EGR-1) DNA consensus sequence 7 present in patients had contraindications to intensive induction treatgrowth factor gene promotors such as the platelet-derived ment and received only hydroxyurea. All patients who achigrowth factor A chain (PDGF-A) promotor and insulin-like eved complete remission (CR) received one to four consoligrowth factor II (IGF-II) promotor. 8, 9 Although WT1 has dation courses including DA, DAV (at full or reduced doses) initially been shown to act as a transcriptional repressor in or high-dose Ara-C. Twenty two patients underwent bone cotransfection assays, its specific function in normal and neomarrow transplantation in first (n = 6) or second (n = 11) CR, plastic tissues remains to be elucidated. Recently, the five patients were transplanted while not in CR (relapse n = 3, expression of WT1-specific mRNA in leukemia-derived cell no remission n = 2). lines and in mononuclear cells from patients with acute samples were collected from eight patients during their course of disease. Mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway) and frozen immediately. Total RNA was extracted from 10 7 cells according to RNAzol B protocol (modified acid guanidinium thiocyanate-phenol-chloroform method). 18 RNA was dissolved in 25 l diethyl-pyrocarbonate-treated water and used directly for reverse transcription. [19] [20] [21] [22] AmpliTaq DNA Polymerase (Perkin Elmer Cetus, Norwalk, CT, USA), 2.5 mm MgCl 2 and 20 pmol of each primer in a total reaction volume of 50 l were used. Amplification was performed in a Perkin Elmer thermocycler during one or, when necessary, two subsequent rounds of PCR, for 35 cycles. The PCR steps included denaturation for 300 s at 94°C initially and 30 s in each subsequent cycle, annealing for 30 s at 64°C and extension for 45 s at 72°C with a final extension step for an additional 7 min. The sequences of the external primers used in the first round of PCR were P1: 21mer 5′-ATg Agg ATC CAT ggg CCA gCA-3′ (sense), P2: 25mer 5′-CCT gCA gAC ACT gAA Cgg TCC CCgA -3′ (antisense) and the sequences of the internal nested primers for the second round were P3: 26mer: 5′-ggg ATC CTC TTg TAC ggT Cgg CATCT-3′ (sense) P4: 29mer: 5′-gAA gCT TAA ggg CTT TTC ACC TgT ATGAg-3′ (antisense). 12, 23 Twenty microliters aliquots of the PCR products were electrophoresed on 1.5% agarose gels stained with ethidium bromide. The gels were photographed with polaroid film (Polaroid 667; Polaroid Ltd, Herts, UK) and documented.
We took precautions to prevent contamination as recommended by Kwok and Higushi. 24 To assess the quality of the mRNA, all samples were analyzed on denaturating formamide agarose gels or amplified by PCR using primers for abl, ␤ 2 -microglobulin or actin c-DNA. Samples that did not amplify with these primers were excluded from analysis. Sample collection, PCR sample preparation, and analysis were performed in different rooms. Only positive displacement pipettes were used. All experiments were run with at least one nega- ensure the specificity and sensitivity of our PCR procedure, hybridization was carried out using an oligonucleotide probe recognizing the WT1 sequence internal to the second-step described previously. 25 A median of 20 metaphases (range 5-100 metaphases) was analyzed. Cytogenetic analysis was sucnested primers, which had been 5′end-labeled with digoxigenin (DIG Nucleic Acid Detection Kit; Boehringer cessful in 115 cases (Table 1) . Mannheim, Biochemie, Mannheim, Germany). The sequence of the oligonucleotide probe is 5′-CCA AAg gAg ACA TAC Agg TgT gAA ACC-3′. The level of sensitivity was 1:100 after Statistical analysis first-step and 1:10 000 after the second-step PCR. The experiment is documented in Figure 1a .
We investigated the influence of WT1 gene expression, karyotype, age, LDH and FAB subtypes on several outcomes. To check effects on response to therapy, we performed logistic regression using the BMDPLR (BMDP 1990, Statistical
Cytogenetics
Software, USA) (main effects) and LogXact 1993, (Cytel Software Corporation, Boston, MA, USA) (interactions) packIn all patients, cytogenetic studies were carried out. Chromosome preparations were done with standard techniques from ages. 26 Overall survival (OS) and disease-free survival (DFS) were investigated by plots of the product-limit estimators 27 bone marrow. Cytogenetic analysis was performed as Response to WT1-positive WT1-negative induction therapy n = 88 n = 28
The frequency of WT1 positivity was similar in younger (Ͻ60 years) and older patients and there was also no difference were similar in WT-positive and -negative patients. The white blood cell count was higher in WT1-negative cases, but the difference was not significant. There was no difference in the frequency of WT1 positivity between immature (M0 and M1) using BMDP1L (BMDP 1990 ) and the proportional hazards and more mature (M2, M4, M5) types of leukemia. Interestmodel using BMDP2L (BMDP 1990) . OS was calculated from ingly, only one of the M3 leukemias was WT1 negative. Comdate of diagnosis to last visit or to date of death, while DFS pared to other FAB types this frequency was not significantly was calculated from date of CR to last visit, relapse or death.
lower (P = 0.11). There was no difference in the WT1 positivPatients undergoing BMT were censored at the time of transity among different categories of karyotype abnormalities. plantation. Comparisons of OS and DFS curves were based on Mantel-Cox 28 and Breslow's 29 tests.
WT1 gene expression and response to treatment

Results
Frequency of WT1 expression
The CR rate was almost identical in WT1-positive and -negative patients (Table 2 ). There was no difference in the OS and DFS (Figure 2 ) among WT1-positive and -negative patients. Ninety-one (73%) patients were WT1 PCR positive. Of these, 30 patients had a strong (first-step positive) and 61 a weak
The relative risk (positive vs negative patients) was 1.012 for OS and 1.001 for DFS (NS). If the relative risk was adjusted (only second-step positive) expression of WT1. Thirty-four (27%) patients were WT1 negative (Table 1) . In all WT1 PCRfor age (Ͻ vs Ͼ60 years), LDH (Ͻ vs Ͼ400 U/l for patients Ͻ60 years; Ͻ vs Ͼ700 U/l for patients Ͼ60 years), FAB positive patients the size of the first-round PCR fragment was 857 bp and 322 bp for the second-step PCR product, respect-(immature vs mature) and karyotype (high risk vs normal and low risk) it was 0.99 for OS and 0.885 for DFS (NS). ively. A representative gel is documented in Figure 1b .
Discussion
Our data confirm reports in previous studies that the WT1 gene is frequently expressed in leukemic blasts of AML patients. The prevalence of positivity (73%) in our study is comparable to that of published studies: 68%, 10 81%, 12,13 93% 14 and 100%. 15 Differences in the methods or selection of patients may account for the small differences. We were not able to correlate WT1 gene expression with other features of the leukemias such as age, sex, cell counts at diagnosis, FAB type, LDH and karyotype. We could not confirm the observation of Brieger et al 12, 13 and Inoue et al 15 that WT1 expression is lower in differentiated forms of AML. Furthermore, we could not confirm previous data that WT1 gene expression seems to be associated with higher 13 or lower 15 CR rates, better 13 or worse 15 DFS and OS. In our hands, WT1 PCR-positive and -negative patients had similar CR rates (Table 2 ) and we found no significant correlation between WT1 gene expression and DFS as well as OS. The discrepancy with the data reported by Inoue et al 15 might be due to the fact that this group included AML and ALL together in the survival analysis.
For the monitoring of minimal residual disease our limited data do not allow any conclusions as to the usefulness of WT1
Figure 2
Probability of disease-free survival in AML patients PCR analysis for the early detection of relapse.
according to Kaplan-Meier calculation in relation to WT1 mRNA When we started this study it was our hope that WT1 expression (88 patients, P = 0.666 Mantel-Cox test, P = 0.286 Bresexpression might be an independent predictor for response to low test).
treatment. Our results clearly show that this is not the case. WT1 expression did not predict for complete remission after induction treatment and OS and DFS were almost identical in
Monitoring of minimal residual disease using WT1
WT-positive and -negative patients. It must be emphasized PCR that this is not a prospective study and the treatment was not completely uniform. The lack of any difference or even a trend We monitored WT1 gene expression during the course of dismakes it unlikely that a prospective trial will show any ease in eight patients who had detectable WT1 mRNA at diagdifferences. nosis and achieved complete hematological remission. Results
Based on our data we conclude that the determination of are shown in Figure 3 . The behavior of WT1 gene expression WT1 expression at diagnosis has currently no practical value in these patients was quite heterogenous and from these limfor the management of patients with AML. A study on the useited data it is not possible to draw any conclusions as to the fulness of WT1 expression as a marker of minimal residual usefulness of the monitoring of WT1 gene expression by PCR leukemia in patients who are WT1 positive at diagnosis is analysis for the prediction of relapse.
ongoing.
